Business Wire

TII

Share
Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Integration of Secure PX4 Stack into RISC-V Based Drone

The Secure Systems Research Centre (SSRC) at Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the launch of its first Reduced Instruction Set Computer (RISC-V) based drone flight controller that leverages the Centre’s own secure PX4 stack. The flight marks a milestone in SSRC’s path to making RISC-V based UAV systems a reality through this successful testing and validation of the RISC-V + the secure PX4 stack system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005440/en/

Earlier this year, the Centre became a strategic member of RISC-V International, a non-profit organisation controlled by its members, which directs the future development and drives the adoption of RISC-V free and open Instruction Set Architecture (ISA). SSRC is focused on building an RISC-V based secure flight computer system. Today’s milestone is a major signpost on this path, with the Centre using a commercially available RISC-V development platform to port the DroneCode PX4 open source software to RISC-V.

Dr. Ray O. Johnson, CEO of TII, said: “RISC-V’s ISA is revolutionising the world of computing systems, and TII is proud to build this capability into our growing collection of breakthrough solutions that are future-proofing our world – one step at a time. We are seeing the use cases for drones and similar autonomous systems now spanning multiple sectors from e-commerce to healthcare and communication to security. This achievement will further strengthen our credibility as a global research centre at the forefront of cutting-edge technology that is working to shape an enabled and more secure world.”

Dr. Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “We are putting TII on the world map as leaders in pioneering Zero Trust Drone System research through this effort. The DroneCode community is the leading open-source community of PX4 Autopilot and fight controller hardware code and specification, respectively. A significant part of the work in realising this project required the porting of NuttX real-time OS and PX4 flight controller software to the RISC-V platform. SSRC has already included some of the planned security improvements into its existing PX4 software stack, and we will continue to develop this software and contribute the modifications back to open source.”

He added: “Through this milestone, we intend to highlight our regional expertise in the research and development of security for Drone and Autonomous Systems, an area that is set to have an outsized impact in shaping the Smart Cities of the future - making them safer and also significantly accelerating the opportunities for new services.”

As a follow-up, SSRC will continue to improve the security and resilience of the open source PX4 flight control software stack and NuttX real-time OS in collaboration with open source community. Furthermore, the Centre has presented a roadmap that includes improving memory protection of NuttX OS and PX4, protecting data on the removable media and utilising commercially available Root-of-Trust components.

Jukka Laitinen, Drone Software Lead Engineer and Architect at the SSRC in TII and Technical Lead for Dronecode Security Special Interest Group also presented a talk on making the current drone platform better, more secure, and resilient at the PX4 Autopilot Development Summit in September 2021.

SSRC is on track to achieving the first TII custom flight controller hardware, with the initial prototypes of this hardware, using a commercial off-the-shelf RISC-V SoC, expected by Q1 2022. This will enable researchers and industry to replace existing commercial flight controllers with a TII secure flight controller.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye